TFF Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
TFF Pharmaceuticals's earnings have been declining at an average annual rate of -17.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 85.6% per year.
Key information
-17.5%
Earnings growth rate
19.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 85.6% |
| Return on equity | -174.2% |
| Net Margin | -2,558.6% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How TFF Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -24 | 12 | 0 |
| 30 Jun 23 | 1 | -27 | 13 | 0 |
| 31 Mar 23 | 0 | -30 | 14 | 0 |
| 31 Dec 22 | 0 | -32 | 14 | 0 |
| 30 Sep 22 | 0 | -34 | 13 | 0 |
| 30 Jun 22 | 0 | -36 | 12 | 0 |
| 31 Mar 22 | 0 | -32 | 11 | 0 |
| 31 Dec 21 | 0 | -31 | 11 | 0 |
| 30 Sep 21 | 0 | -27 | 10 | 0 |
| 30 Jun 21 | 0 | -23 | 10 | 0 |
| 31 Mar 21 | 0 | -22 | 9 | 0 |
| 31 Dec 20 | 0 | -19 | 8 | 0 |
| 30 Sep 20 | 0 | -41 | 7 | 3 |
| 30 Jun 20 | 0 | -39 | 5 | 6 |
| 31 Mar 20 | 0 | -38 | 4 | 7 |
| 31 Dec 19 | 0 | -37 | 3 | 9 |
| 30 Sep 19 | 0 | -9 | 3 | 6 |
| 30 Jun 19 | 0 | -7 | 3 | 3 |
| 31 Mar 19 | 0 | -7 | 3 | 3 |
| 31 Dec 18 | 0 | -5 | 3 | 1 |
| 30 Sep 18 | 0 | -4 | 2 | 1 |
| 30 Jun 18 | 0 | -3 | 2 | 1 |
| 31 Mar 18 | 0 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
Quality Earnings: 0K30 is currently unprofitable.
Growing Profit Margin: 0K30 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0K30 is unprofitable, and losses have increased over the past 5 years at a rate of 17.5% per year.
Accelerating Growth: Unable to compare 0K30's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0K30 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4%).
Return on Equity
High ROE: 0K30 has a negative Return on Equity (-174.23%), as it is currently unprofitable.